
Lotte Biologics announced on the 17th that it has signed a contract manufacturing organization (CMO) agreement for biologics with a global pharmaceutical company.
This contract is the first large-scale commercial production order to be manufactured at Plant 1, which Lotte Biologics built at its Incheon Songdo Bio Campus. The company emphasized that securing a global pharmaceutical company as a commercial production partner ahead of the plant’s completion is significant in demonstrating market confidence in its process technology and business stability.
However, details such as the name of the contracted product and the contract size were not disclosed due to confidentiality clauses with the client.
Under this contract, Lotte Biologics plans to provide a “One-Stop Service” covering all stages of product production for the client’s key products, from the manufacture of clinical-stage drug substances to finished pharmaceuticals.
Through this contract, Lotte Biologics has proactively secured commercial production volumes necessary for initial operations following the completion of Songdo Plant 1.
Lotte Biologics’ Songdo Plant 1 is a state-of-the-art biologics manufacturing facility with a total capacity of 120,000 liters, equipped with eight stainless steel bioreactors of 15,000-liter capacity each. The company aims to fully commence commercial production next year.
Lotte Biologics is pursuing the diversification of its global supply chain based on a “Dual-Site” strategy that links the commercial production experience at its Syracuse Bio Campus in the United States with the large-scale production capabilities of the Songdo Campus. The company stated that it has secured relatively stable production capabilities based on more than 62 regulatory agency approvals accumulated at the U.S. Syracuse Bio Campus.
Since obtaining usage approval for Songdo Plant 1 last June, Lotte Biologics has been expanding cooperation with global pharmaceutical and biotechnology companies to secure contract wins.
Park James, CEO of Lotte Biologics, said, “This contract is a result showing that Lotte Biologics has positioned itself not merely as a new entrant in the CDMO (Contract Development and Manufacturing Organization) space, but as a core supply chain partner for global clients.” He added, “Based on our accumulated quality competitiveness and stable supply capabilities, we will actively support the successful commercialization of new drugs by our clients.”